GoodRx Holdings, Inc. (GDRX)
NASDAQ: GDRX · Real-Time Price · USD
2.680
0.00 (0.00%)
At close: Jan 16, 2026, 4:00 PM EST
2.700
+0.020 (0.75%)
After-hours: Jan 16, 2026, 7:42 PM EST
GoodRx Holdings Revenue
GoodRx Holdings had revenue of $196.03M in the quarter ending September 30, 2025, with 0.40% growth. This brings the company's revenue in the last twelve months to $800.65M, up 1.30% year-over-year. In the year 2024, GoodRx Holdings had annual revenue of $792.32M with 5.61% growth.
Revenue (ttm)
$800.65M
Revenue Growth
+1.30%
P/S Ratio
1.23
Revenue / Employee
$1,084,893
Employees
738
Market Cap
909.68M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 792.32M | 42.06M | 5.61% |
| Dec 31, 2023 | 750.27M | -16.29M | -2.12% |
| Dec 31, 2022 | 766.55M | 21.13M | 2.83% |
| Dec 31, 2021 | 745.42M | 194.72M | 35.36% |
| Dec 31, 2020 | 550.70M | 162.48M | 41.85% |
| Dec 31, 2019 | 388.22M | 138.70M | 55.59% |
| Dec 31, 2018 | 249.52M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GDRX News
- 4 days ago - GoodRx Holdings, Inc. (GDRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - Surescripts and GoodRx Partner to Advance Patient Price Transparency - Business Wire
- 9 days ago - GoodRx Launches RxSmartSaver at Giant Eagle Pharmacies - Business Wire
- 12 days ago - GoodRx Now Offers Novo Nordisk's Cash Price for the Launch of the Wegovy® Pill - Business Wire
- 4 weeks ago - GoodRx to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - GoodRx Launches New $39 Per Month Weight Loss Telemedicine Subscription, Unveils Industry-Leading Introductory Cash Price of $199 Per Month for Ozempic® and Wegovy® - Business Wire
- 2 months ago - GoodRx Holdings, Inc. (GDRX) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - GoodRx Sees ‘Profund Transformation' in Prescriptions With TrumpRx - PYMNTS